Empath Ventures
VC Fund
Los Angeles, United States
Empath Ventures is a venture capital firm that mainly invests in psychedelic medicine companies. The firm specializes in the fields of investment financial services, finance, and venture capital. It was founded in 2021 and headquartered in Los Angeles California.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Empath Ventures invests in
Stages Empath Ventures invests in
Countries Empath Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1.6M–$12M
Investment Focus
Industry
- Health Care 7 (39%)
- Biotechnology 6 (33%)
- Personal Health 4 (22%)
- Wellness 3 (17%)
- Therapeutics 3 (17%)
Stage
- Seed 10 (56%)
- Pre-Seed 3 (17%)
- Convertible Note 2 (11%)
- Series A 1 (6%)
- Venture - Series Unknown 1 (6%)
Country
- United States 9 (50%)
- United Kingdom 3 (17%)
- Canada 1 (6%)
- Mexico 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brom Rector
Founder
|
Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xylo Bio
|
Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications. | $8M / Seed / Jun 02, 2024 | |
Aperture Therapeutics
|
Aperture Therapeutics is a biotechnology company focused on the development of novel therapies for age-related neurodegenerative diseases. Utilizing a unique drug discovery platform, the company aims to harness the genetic diversity of patients to identify new disease pathways and drug targets. With operations based in a lab incubator, ApertureTherapeutics is in the pre-clinical stage, actively applying insights from neuroscience and immunology to advance its research. The company's approach emphasizes the importance of genetic diversity in the discovery process, aiming to lead to more effective treatments for neurodegeneration and neuroimmunology conditions. | Pre-Seed / Feb 01, 2024 | |
Motif Neurotech
|
Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $18.8M / Series A / Jan 24, 2024 | |
TARA Mind
|
Tara Mind provides safe and equitable access to psychedelic-assisted therapy in order to prevent mental health crises. | $8M / Seed / Jan 23, 2024 | |
NUE Life Health
|
NUE Life aims to improve mental wellness by enhancing brain function, performance, and longevity through evidence-based and scientifically proven mental health treatments and products. NUE Life has created a therapeutic ecosystem of ketamine therapy, an interactive companion app, and virtual aftercare programs to help people heal. | $1.9M / Venture - Series Unknown / Jun 15, 2023 | |
|
Motif Neurotech
|
Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $2M / Seed / Feb 28, 2023 | |
Superpower
|
The world's most comprehensive and convenient platform to manage your health, for life. | Seed / Jan 01, 2023 | |
|
Superpower
|
The world's most comprehensive and convenient platform to manage your health, for life. | Pre-Seed / Jan 01, 2023 | |
|
Xylo Bio
|
Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications. | $3.2M / Seed / Oct 27, 2022 | |
Pangea Bio
|
Pangea Botanica helps to accelerate the discovery and development of therapeutics for patients by using naturally occurring compounds and traditional remedies, while preserving ethnobotanical knowledge and ecosystems. It is a biotechnology research organisation that offers drug discovery and development services. | Convertible Note / Oct 10, 2022 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Empath Ventures invest in?
Empath Ventures invests primarily in Health Care, Biotechnology and Personal Health startups, most often at Seed and Pre-Seed stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Empath Ventures's check size?
Empath Ventures typically joins rounds of $1.6M–$12M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Empath Ventures participates in.
How do I contact Empath Ventures?
Public channels for Empath Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Empath Ventures?
The team at Empath Ventures includes Brom Rector (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
